Braeden Lichti and Northstrive Fund II LP Exit Position in Bluejay Diagnostics, Inc.

On June 2, 2026, Braeden Lichti and Northstrive Fund II LP filed Amendment No. 1 to their Schedule 13D, disclosing the complete disposition of their holdings in Bluejay Diagnostics, Inc. (BJDX). The reporting persons previously filed an initial Schedule 13D on March 11, 2026. This amendment serves as an exit filing, as both Mr. Lichti and Northstrive Fund II LP have sold all previously owned shares of the Issuer's common stock. Consequently, the reporting persons no longer beneficially own any shares and have ceased to be owners of more than five percent of the company's outstanding common stock. Mr. Lichti, a citizen of Canada and CEO of Northstrive Companies Inc., served as the Manager of Northstrive Fund II LP. The filing confirms that no shares were acquired since the initial March filing and that the reporting persons now hold zero voting or dispositive power over the Issuer's securities. This filing marks the final amendment to their Schedule 13D.